Nanobiotix (NASDAQ:NBTX) Reaches New 12-Month High – Still a Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares hit a new 52-week high on Friday . The stock traded as high as $57.14 and last traded at $55.07, with a volume of 142428 shares changing hands. The stock had previously closed at $52.04.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on NBTX shares. Guggenheim raised their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. UBS Group raised their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Finally, TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $26.67.

Nanobiotix Price Performance

The business’s 50-day simple moving average is $34.73 and its 200 day simple moving average is $26.56.

Nanobiotix (NASDAQ:NBTX) last posted its earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The business had revenue of $3.42 million for the quarter. On average, equities analysts expect that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current year.

Institutional Investors Weigh In On Nanobiotix

Large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new position in shares of Nanobiotix during the 4th quarter worth $390,000. Marshall Wace LLP bought a new stake in shares of Nanobiotix during the 4th quarter valued at $220,000. Optiver Holding B.V. bought a new stake in shares of Nanobiotix during the 3rd quarter valued at $101,000. Finally, Royal Bank of Canada grew its position in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares during the period. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.